newsfilter
← Latest News
GlobeNewswire·

Jounce Therapeutics Reports Second Quarter 2022 Financial Results

- INNATE trial of JTX-8064 +/- pimivalimab on track to present preliminary data on at least 80 Phase 2 patients across multiple cohorts by year end - - Patient enrollment complete in the randomized, Phase 2 SELECT trial of vopratelimab in combinatio